100 Park Avenue
23rd Floor
New York, NY 10017
United States
646 677 3870
https://www.actiniumpharma.com
Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 49
Name | Title | Pay | Exercised | Year Born |
---|---|---|---|---|
Mr. Sandesh C. Seth M.B.A., M.S. | Chairman & CEO | 1.21M | N/A | 1964 |
Mr. Steven O'Loughlin BS | CFO & Corporate Secretary | 590k | N/A | 1986 |
Dr. Paul Diamond Esq., Ph.D. | Vice President of Patent & Legal Counsel | N/A | N/A | N/A |
Dr. Avinash Desai M.D. | Chief Medical Officer | N/A | N/A | N/A |
Ms. Jenny Hsieh | Chief Strategy Officer | N/A | N/A | N/A |
Ms. Sunitha Lakshminarayanan | Senior VP, Head of CMC & Product Development | N/A | N/A | N/A |
Ms. Caroline Yarbrough | Chief Commercial Officer | N/A | N/A | N/A |
Ms. Lynn M. Bodarky M.B.A. | Chief Business Officer | N/A | N/A | 1966 |
Mr. J. C. Simeon | Executive Director of Quality Assurance | N/A | N/A | N/A |
Dr. Madhuri Vusirikala M.D. | Vice President of Clinical Development BMT & Cellular Therapy | N/A | N/A | N/A |
Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted radiotherapies to deliver cancer-killing radiation to treat patients with high unmet medical needs. Its lead product candidate, Iomab-B (I-131 apamistamab) that is in a pivotal Phase III clinical trial for people with relapsed and refractory acute myeloid leukemia for bone marrow transplant; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center. The company offers clinical and preclinical development programs that utilize multiple isotopes, including Actinium-225, Iomab-ACT for GeneTx and cell therapy conditioning, Actimab-A (CD33) and CLAG-M, Actimab-A (CD33) and Venetoclax, and Actimab-A (CD33) and Venetoclax with HMA. It has collaboration with Astellas Pharma, Inc. to develop theranostics for solid tumor indications; EpicentRx, Inc that focuses on a novel CD47 -SIRPa immunotherapy targeted radiotherapy; and Immedica pharma for licensed the rights to commercialize Iomab-B. The company is based in New York, New York.
Actinium Pharmaceuticals, Inc.’s ISS Governance QualityScore as of July 1, 2024 is 10. The pillar scores are Audit: 9; Board: 9; Shareholder Rights: 6; Compensation: 10.